Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Elevance Health (ELV)

Elevance Health reports Q1 GAAP EPS of $9.61, adjusted $11.97; reaffirms 2025 guidance

Mixed Impact 3 of 5 earnings Written later

Elevance Health said it expects first quarter 2025 GAAP net income of $9.61 per diluted share, including about $2.36 per diluted share of net unfavorable items, and adjusted net income of $11.97 per diluted share. The company reaffirmed full-year 2025 adjusted net income guidance of $34.15 to $34.85 per diluted share, and said Medicare Advantage cost trends were in line with its expectations, though still elevated. Full results are due April 22, 2025.

Key points

  • Q1 2025 GAAP net income expected at $9.61 per diluted share, including about $2.36 per diluted share of net unfavorable items
  • Q1 2025 adjusted net income expected at $11.97 per diluted share
  • Full-year 2025 adjusted net income guidance reaffirmed at $34.15 to $34.85 per diluted share
  • Full-year 2025 Medicare Advantage membership expected at 2,200 to 2,250 thousand members; full results due April 22, 2025

The filing

CompanyElevance Health (ELV)
Form8-K, current report
Filed with the SECApr 17, 2025, 10:24 AM ET
Accession number0001156039-25-000051

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:21 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 17, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.